A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：CLINICAL PROTEOMICS ISSN： 1542-6416 出版频率： Continuous publication 出版社： BMC, CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW   出版社网址： http://www.biomedcentral.com/ 期刊网址： http://clinicalproteomicsjournal.biomedcentral.com/ 影响因子： 3.988 主题范畴： BIOCHEMICAL RESEARCH METHODS 变更情况： Newly Added by 2016 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and scope Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.  A key feature of Clinical Proteomics is its commitment to rapid scientific review and timely publication of submitted manuscripts. This is achieved receiving and processing submissions online. As molecular medicine moves beyond genomics to proteomics, the goal becomes the characterization of the cellular circuitry and the understanding of the impact of disease and therapy on cellular networks. Clinical Proteomics provides a scholarly forum for novel scientific research in the field of translational proteomics. The journal places special emphasis on the application of proteomic technology to all aspects of clinical research. A key feature is its commitment to rapid scientific review and timely publication of submitted manuscripts. Open access All articles published by Clinical Proteomics are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here. As authors of articles published in Clinical Proteomics you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement. For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed. Article-processing charges Open access publishing is not without costs. Clinical Proteomics therefore levies an article-processing charge of £1370/$2145/€1745 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page. Indexing services All articles published in Clinical Proteomics are included in: Cinahl Citebase DOAJ Embase Index to Chiropractic Literature OAIster PubMed PubMed Central Scopus SOCOLAR ​Zetoc The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.  Clinical Proteomics has an Impact Factor of 3.476. Peer-review policy Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here. Clinical Proteomics operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript. Manuscripts will be assigned to a handling Editor, who will appoint at least two referees. On receipt of their reports the handling Editor will make a recommendation to accept, to accept with minor revisions, to request major revisions and resubmission, or to reject. No manuscript will be rejected without being assessed by a member of the Editorial Board and one other expert. Clinical Proteomics considers the following types of article: Letter to the Editor, Meeting report, Research, and Review. For more specific information, please take a look at our Submission Guidelines. Editorial policies All manuscripts submitted to Clinical Proteomics should adhere to BioMed Central's editorial policies. Citing articles in Clinical Proteomics Articles in Clinical Proteomics  should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number. Article citations follow this format: Authors: Title. Clin Proteomics [year], [volume number]:[article number]. e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Proteomics 2009, 1:115. refers to article 115 from Volume 1 of the journal. Appeals and complaints If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher. Why publish your article in Clinical Proteomics High visibility Clinical Proteomics's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.  Speed of publication Clinical Proteomics offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF. Flexibility Online publication in Clinical Proteomics gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles). Promotion and press coverage Articles published in Clinical Proteomics are included in article alerts and regular email updates. Some may be highlighted on Clinical Proteomics’s pages and on the BioMed Central homepage. In addition, articles published in Clinical Proteomics may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical Proteomics. A list of articles recently press-released by journals published by BioMed Central is available here. Copyright As an author of an article published in Clinical Proteomics you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement). For further information about the advantages of publishing in a journal from BioMed Central, please click here. Instructions to Authors Submission guidelines Our 3-step submission process Before you submit Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit. Make sure you are submitting to the most suitable journal - Aims and scope Understand the costs and funding options - Fees and funding Make sure your manuscript is accurate and readable - Language editing services Understand the copyright agreement - Copyright Ready to submit To give your manuscript the best chance of publication, follow these policies and formatting guidelines. Clinical Proteomics publishes the following article types: Letter to the Editor Meeting report Research Review Click the relevant link to find style and formatting information for the article you are going to submit. General formatting rules for all article types - Preparing your manuscript Make sure your submission is complete - Prepare supporting information Copyright and license agreement - Conditions of publication Read and agree to our Editorial Policies - Editorial policies Submit and promote After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond. Who decides whether my work will be accepted? - Peer-review policy Want to submit to a different journal? - Manuscript transfers Spreading the word - Promoting your publication Submit your manuscript in Editorial Manager Editorial Board Editor-in-Chief Prof Daniel W Chan, Johns Hopkins University, USA Associate Editors Prof Mark S Baker, Macquarie University, Australia Prof Bruno Domon, Luxembourg Clinical Proteomics Center, Luxembourg Prof Tim Griffin, University of Minnesota, USA  Dr Jacob Kagan, National Cancer Institute, USA Dr Stephen R Master, Weill Cornell Medical College, USA Prof Ed Nice, Ludwig Institute for Cancer Research, Australia Prof Terence CW Poon, University of Macau, China Prof KW Michael Siu, University of Windsor, Canada Dr Hui Zhang, Johns Hopkins Medical Institutions, USA Senior Editors Prof Denis Hochstrasser, Geneva University, Switzerland Prof Gilbert S Omenn, University of Michigan, USA Dr Richard D Smith, Pacific Northwest National Laboratory, USA Editorial Board Prof Dr Ruedi Aebersold, ETH Zurich, Switzerland Dr Leigh Anderson, Plasma Proteome Institute, USA Dr Christoph Borchers, University of Victoria, Canada Dr Maria Chan, Food and Drug Administration, USA  Prof Catherine E Costello, Boston University, USA Dr Mari DeMarco, University of British Columbia, Canada Prof Eleftherios P Diamandis, University of Toronto, Canada Dr Andrei Drabovich, University of Toronto, Canada Prof Catherine Fenselau, University of Maryland, USA Dr Brian Haab, Van Andel Institute, USA Prof Samir Hanash, Fred Hutchinson Cancer Research Center, USA Prof Fuchu He, Beijing Institute of Radiation Medicine, China Dr Andrew Hoofnagle, University of Washington, USA Dr Saeed Jortani, University of Louisville, USA Dr Scott Kuzdzal, Shimadzu Scientific Instruments, UK Prof Joshua LaBaer, Arizona State University, USA Dr Danni Li, University of Minnesota, USA  Prof Yan Li, Chinese Academy of Sciences, China Prof Joseph Loo, University of California Los Angeles, USA Dr Mary F Lopez, Nuclea Biotechnologies, USA Prof John G Marshall, Ryerson University, Canada Prof Michael Moran, University of Toronto, Canada Prof Fumio Nomura, Chiba University, Japan Prof Nicolle Packer, Macquarie University, Australia Prof Young-Ki Paik, Yonsei University, South Korea Prof Akhilesh Pandey, Johns Hopkins University, USA Prof Peipei Ping, University of California Los Angeles, USA Dr Alex Rai, Columbia University, USA Prof James Ritchie, Emory University, USA Dr Karin Rodland, Pacific Northwest National Laboratory, USA Dr Henry Rodriguez, National Cancer Institute, USA Prof Jean-Charles Sanchez, Centre Medical Universitaire, Switzerland Dr Richard Semba, Johns Hopkins School of Medicine, USA Dr Steven Skates, Harvard University, USA Prof Michael Snyder, Stanford University, USA Dr Pothur Srinivas, National  Institutes of Health, USA Dr Sudhir Srivastava, National Institute of Health, USA Prof Naoyuki Taniguchi, RIKEN Advanced Science Institute, Japan Prof Jennifer van Eyk, Johns Hopkins University, USA Dr Timothy D Veenstra, National Institutes of Health, USA Prof Marc R Wilkins, University of New South Wales, Australia Dr Bing Zhang, Vanderbilt University, USA Dr Zhen Zhang, Johns Hopkins Medical Institutions, USA Prof Yingming Zhao, The University of Chicago, USA Dr Heng Zhu, Johns Hopkins University, USA